Literature DB >> 16001356

[GPS--good practice secondary data analysis. Working Group for the Survey and Utilization of Secondary Data (AGENS) of the German Society for Social Medicine and Prevention (DGSMP)].

E Swart1, P Ihle, S Geyer, T Grobe, W Hofmann.   

Abstract

The scientific use of secondary data, especially of claims data from health insurance funds, has continuously increased in the last years. Therefore the Working Group "Collection and Use of Secondary Data" (AGENS) of the German Society of Social Medicine and Prevention (DGSMP) took the initiative to define quality standards for secondary data analysis. Starting with a review of the Good Epidemiologic Practice (GEP) AGENS adapted the GEP to the specific requirements of secondary data analysis by a multi-stage consensus process. The guideline Good Practice Secondary Date Analysis (GPS) was adopted on January 15 (th), 2005. GPS consists of 10 guidelines which are divided in explaining comments and recommendations. The GPS are targeted to set up standards for secondary data analysis, and they may also be used as a foundation of contracts between data owners and scientists. They are addressed to scientists from health services research and social medicine. AGENS commits itself to revise GPS continuously.

Mesh:

Year:  2005        PMID: 16001356     DOI: 10.1055/s-2005-858356

Source DB:  PubMed          Journal:  Gesundheitswesen        ISSN: 0941-3790


  9 in total

1.  Varicella vaccination coverage of children under two years of age in Germany.

Authors:  Annicka M Reuss; Marcel Feig; Lutz Kappelmayer; Anette Siedler; Tim Eckmanns; Gabriele Poggensee
Journal:  BMC Public Health       Date:  2010-08-19       Impact factor: 3.295

2.  [Health services research activities in North Rhine-Westphalia. An analysis of the project database health services research NRW].

Authors:  Gisela Nellessen-Martens; Elke Driller; Ludger Pientka; Holger Pfaff
Journal:  Med Klin (Munich)       Date:  2009-06-16

3.  [Memorandum III "methods for health services research", Part 1 [authors: H. Pfaff, G. Glaeske, E. A. M. Neugebauer, M. Schrappe] and Part 2 [authors: E. A. M. Neugebauer, A. Icks, M. Schrappe] of the Deutsches Netzwerk Versorgungsforschung e.V.: A summary].

Authors:  Ursula Dietrich; Kerstin Thümmler; Ursula Schütte; Michael Walter; Wilhelm Kirch
Journal:  Med Klin (Munich)       Date:  2011-01-16

4.  [A standard data set for the evaluation of venous leg ulcers in selective contracts : National consensus].

Authors:  K Heyer; S Milde; J Schmitt; M May; J Helfrich; M Augustin
Journal:  Hautarzt       Date:  2017-10       Impact factor: 0.751

5.  Epidemiology and use of compression treatment in venous leg ulcers: nationwide claims data analysis in Germany.

Authors:  Kristina Heyer; Kerstin Protz; Gerd Glaeske; Matthias Augustin
Journal:  Int Wound J       Date:  2016-05-19       Impact factor: 3.315

6.  Cost Analysis of Integrative Inpatient Treatment Based on DRG Data: The Example of Anthroposophic Medicine.

Authors:  Jürgen Heinz; Wolfgang Fiori; Peter Heusser; Thomas Ostermann
Journal:  Evid Based Complement Alternat Med       Date:  2013-01-31       Impact factor: 2.629

7.  Epidemiology and cost of herpes zoster and postherpetic neuralgia in Germany.

Authors:  Bernhard Ultsch; Ingrid Köster; Thomas Reinhold; Anette Siedler; Gérard Krause; Andrea Icks; Ingrid Schubert; Ole Wichmann
Journal:  Eur J Health Econ       Date:  2012-12-28

8.  Evaluation of Quality Indicators of Integrated Care in a Regional Psychiatry Budget - A Pre-Post Comparison by Secondary Data Analysis.

Authors:  Anne Berghöfer; Svenja Hubmann; Thomas Birker; Torsten Hejnal; Felix Fischer
Journal:  Int J Integr Care       Date:  2016-12-31       Impact factor: 5.120

9.  Adherence to Disease Modifying Drugs among Patients with Multiple Sclerosis in Germany: A Retrospective Cohort Study.

Authors:  Kerstin Hansen; Katrin Schüssel; Marita Kieble; Johanna Werning; Martin Schulz; Robert Friis; Dieter Pöhlau; Norbert Schmitz; Joachim Kugler
Journal:  PLoS One       Date:  2015-07-27       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.